Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;21(1):54-61.
doi: 10.1111/vco.12860. Epub 2022 Oct 7.

Treatment of myeloid neoplasia with doxorubicin and cytarabine in 11 dogs

Arata Matsuyama  1 , Janet Beeler-Marfisi  2 , R Darren Wood  2 , Danielle Richardson  3 , Jerome Calvalido  4 , Anthony J Mutsaers  1   3 , Dorothee Bienzle  2
Affiliations

Treatment of myeloid neoplasia with doxorubicin and cytarabine in 11 dogs

Arata Matsuyama et al. Vet Comp Oncol. 2023 Mar.

Abstract

Myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) are primary myeloid neoplasms in dogs generally considered to have a poor outcome. In this study, we assessed toxicity, efficacy and outcome of concurrent administration of doxorubicin and cytarabine in 11 dogs with myeloid neoplasia. Bone marrow specimens were reviewed by three pathologists and classified as either MDS (n = 2), high grade MDS/early AML (MDS/AML; n = 4) or AML (n = 5). The median number of treatment cycles was 5 (range 1-9) and resolution of cytopenia was reported in 7 of 11 dogs including 2 dogs with MDS, 2 dogs with MDS/AML, and 3 dogs with AML. The median duration of remission in the seven responders was 344 days (range 109-1428) and the median overall survival for all dogs was 369 days. Adverse events consisted of predominantly low-grade gastrointestinal illness and myelosuppression. Three dogs developed grade V toxicity manifesting with heart failure (n = 2) at 369 and 1170 days after diagnosis and acute gastrointestinal side effects (n =1). Despite a limited sample size, these results suggest that a doxorubicin and cytarabine protocol may be considered as a therapeutic option in dogs with myeloid neoplasia. Protocol safety, in particular regarding myocardial toxicity, and efficacy should be further investigated.

Keywords: acute myeloid leukaemia; chemotherapy; clinical pathology; dog; myelodysplastic syndrome.

PubMed Disclaimer

References

REFERENCES

    1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
    1. Jain NC, Blue JT, Grindem CB, et al. Proposed criteria for classification of acute myeloid leukemia in dogs and cats. Vet Clin Pathol. 1991;20(3):63-82.
    1. Juopperi TA, Bienzle D, Bernreuter DC, Vernau W, Thrall MA, McManus PM. Prognostic markers for myeloid neoplasms: a comparative review of the literature and goals for future investigation. Vet Pathol. 2011;48(1):182-197.
    1. Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(11):1399-1420.
    1. Fujino Y, Tezuka K, Hisasue M, Masuda K, Ohno K, Tsujimoto H. Clinicopathological features and therapy of myelodysplastic syndromes in two dogs. Vet Rec. 2003;153(1):25-27.

MeSH terms